HIGHLIGHTS
- who: Ernesto Canalis and collaborators from the Musculoskeletal Institute, UConn Health, Farmington, Connecticut, United of America, Ionis Editor: Gary Stein, University of Vermont, UNITED have published the research work: Use of antisense oligonucleotides to target Notch3 in skeletal cells, in the Journal: PLOS ONE of 17/02/2022
- what: The authors explored whether Notch3 antisense oligonucleotides (ASO) downregulate Notch3 and have the potential to ameliorate the osteopenia of Notch3em1Ecan mice. The funders of this work had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.